In Brief: Pharmacia & Upjohn
This article was originally published in The Tan Sheet
Executive Summary
Pharmacia & Upjohn: Consumer Health sales fell nearly 20% to $138 mil. in the third quarter and were down 18% to $458 mil. in the nine months ended Sept. 30, the firm said Oct. 31. P&U points to generic competition for Rogaine 2% minoxidil hair regrowth treatment as well as wholesaler inventory reductions in anticipation of the approval of Rogaine Extra Strength for Men (5% minoxidil) as reasons for the drop. P&U's consolidated results were down as well. Overall sales declined 10% to $1.6 bil. in the third quarter, and net earnings fell 20% to $184 mil. In the nine months, sales decreased 7% to $4.9 bil. and net income dropped 24% to $556 mil...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning